Jeuveau maker posts 21% YoY growth and narrows losses as profitability streak extends.
Evolus reported Q2 2026 revenue of $84.1 million, up 21% year-over-year, and raised full-year 2026 guidance following the beat. The neuromodulator and device company achieved break-even on an adjusted EBITDA basis, extending its streak of profitability quarters as gross margins held steady.
Jeuveau continues to drive growth across the toxin portfolio, with the company maintaining pricing discipline and market share gains in the U.S. aesthetic market. Perceptive Advisors LLC acquired a new stake in Evolus during the quarter, signaling institutional confidence in the turnaround narrative.
Revenue up 21% YoY; adjusted EBITDA margin now positive.
For practice owners tracking the competitive toxin landscape, Evolus's sustained margin expansion and guidance raise matter: the company is proving unit economics can improve even as the market fragments. Jeuveau's trajectory—especially relative to Revance's Daxxify and AbbVie's BOTOX—remains a bellwether for non-legacy toxin adoption.
Source: original report ↗
Frequently asked questions
What was Evolus Q2 2026 revenue and growth rate?
Evolus reported Q2 2026 revenue of $84.1 million, representing 21% year-over-year growth. The company also raised full-year 2026 guidance following the beat, signaling confidence in sustained momentum.
Is Evolus profitable yet?
Yes, Evolus achieved break-even on an adjusted EBITDA basis in Q2 2026 and has extended its streak of profitability quarters. The company is maintaining steady gross margins while improving unit economics.
How does Jeuveau compare to BOTOX and Daxxify in the market?
Jeuveau continues to drive growth across Evolus's toxin portfolio with maintained pricing discipline and market share gains in the U.S. aesthetic market. Jeuveau's trajectory relative to Revance's Daxxify and AbbVie's BOTOX is considered a key bellwether for non-legacy toxin adoption among practices.
What does Evolus's profitability mean for medspa owners?
Evolus's sustained margin expansion and profitability streak demonstrate that unit economics can improve even as the neuromodulator market fragments. This signals viable competition to legacy toxins and pricing sustainability for practices offering multiple toxin options.
Who is investing in Evolus and why?
Perceptive Advisors LLC acquired a new stake in Evolus during Q2 2026, signaling institutional confidence in the company's turnaround narrative and long-term competitive positioning in the aesthetic market.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
